Lifeward (NASDAQ:LFWD) & ClearPoint Neuro (NASDAQ:CLPT) Critical Review

Lifeward (NASDAQ:LFWD – Get Free Report) and ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends.

Insider and Institutional Ownership

26.8% of Lifeward shares are owned by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are owned by institutional investors. 1.1% of Lifeward shares are owned by company insiders. Comparatively, 6.9% of ClearPoint Neuro shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Lifeward and ClearPoint Neuro”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lifeward $22.03 million 0.41 -$19.91 million ($15.74) -0.20
ClearPoint Neuro $36.97 million 6.83 -$25.54 million ($1.21) -6.51

Lifeward has higher earnings, but lower revenue than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Lifeward has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Lifeward and ClearPoint Neuro, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lifeward 1 1 2 0 2.25
ClearPoint Neuro 1 0 2 0 2.33

Lifeward currently has a consensus target price of $8.00, indicating a potential upside of 148.83%. ClearPoint Neuro has a consensus target price of $24.33, indicating a potential upside of 208.84%. Given ClearPoint Neuro’s stronger consensus rating and higher probable upside, analysts plainly believe ClearPoint Neuro is more favorable than Lifeward.

Profitability

This table compares Lifeward and ClearPoint Neuro’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lifeward -155.37% -295.75% -82.97%
ClearPoint Neuro -79.43% -170.24% -37.00%

Summary

ClearPoint Neuro beats Lifeward on 11 of the 13 factors compared between the two stocks.

About Lifeward

(Get Free Report)

Lifeward Ltd. develops and markets medical devices for mobility, rehabilitation and physical therapy. Its products include wearable robotic exoskeletons designed to help people with mobility impairments stand and walk, as well as systems used in rehabilitation settings. The company’s offerings include the ReWalk exoskeleton for people with spinal cord injuries and the ReStore exo-suit for gait training after stroke. Lifeward also sells AlterG anti-gravity treadmills, which use differential air pressure to reduce the user’s effective body weight during walking or running exercises.

About ClearPoint Neuro

(Get Free Report)

ClearPoint Neuro develops technologies used to plan, guide and monitor minimally invasive procedures in the brain and spine. Its product portfolio includes MRI-guided navigation systems and instruments for neurosurgery, including tools for laser ablation and for delivering therapeutics to targeted areas of the central nervous system. The company also works with biotechnology and pharmaceutical partners on the delivery of cell and gene therapies and other biologics to the brain. Its platforms are designed to support accurate placement and monitoring during procedures and in clinical research.

Receive News & Ratings for Lifeward Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifeward and related companies with MarketBeat.com's FREE daily email newsletter.